1) Chen S and Parmigiani G : Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25 : 1329─1333, 2007
2) Iqbal J, Ragone A, Lubinski J, et al : The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 107 : 2005─2009, 2012
3) Li X, You R, Wang X, et al : Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers : A Meta-analysis and Systematic Review. Clin Cancer Res 22 : 3971─3981, 2016
4) Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al : Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer : a prospective analysis. Int J Cancer 136 : 668─677, 2015
5) Domchek SM, Friebel TM, Singer CF, et al : Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304 : 967─975, 2010
6) Mitra AV, Bancroft EK, Barbachano Y, et al : Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer : preliminary analysis of the results of the IMPACT study : BJU Int 107 : 28─39, 2011
7) Castro E, Goh C, Olmos D, et al : Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31 : 1748─1757, 2013
). Genetic/Familial High-Risk Assessment : Breast and Ovarian. Version2. 2019-July 30, 2018